COVID-19 vaccines coverage and effectiveness against SARS-CoV-2 infection among residents in the largest Health Authority of Lazio region (Italy): a population-based cohort study.

Booster dose COVID-19 SARS-CoV-2 infection Socio-demographic characteristics cohort study vaccine coverage vaccine effectiveness waning effect

Journal

Expert review of vaccines
ISSN: 1744-8395
Titre abrégé: Expert Rev Vaccines
Pays: England
ID NLM: 101155475

Informations de publication

Date de publication:
08 2022
Historique:
pubmed: 19 5 2022
medline: 16 8 2022
entrez: 18 5 2022
Statut: ppublish

Résumé

The waning of the protective effect of COVID-19 vaccines and timing of booster doses are debated. Population-based cohort study in the largest Health-Authority of Lazio region, Italy, on 946,156 residents aged 12+ (study period: 1 January 2021-10 January 2022). Vaccine effectiveness (VE) against any SARS-CoV-2 infection (symptomatic or asymptomatic) was estimated through multivariable negative-binomial models using unvaccinated person-time as a reference. The primary vaccination cycle was completed by 81% of residents; of these, 45% received a booster dose. Vaccine coverages were lower for foreigners, and people living in deprived areas, families with children aged 0-11, and households size 1 or 6+. Overall, VE waned from 71% (95% Confidence Interval (CI) 70-73%) 1 month after the second dose to 43% (CI 41-45%) after 4 months and 24% (CI 21-27%) after 6 months, especially in the elderly aged 70+. We observed a prompt restore of VE 15-19 days after the booster dose (69%, CI 67-70%). Our results support the recommendation of a booster dose 4 months after completion of the primary cycle, giving priority to elderly and fragile individuals. The lower vaccine coverage among social disadvantaged subgroups suggests the need of targeted communication and interventions.

Sections du résumé

BACKGROUND
The waning of the protective effect of COVID-19 vaccines and timing of booster doses are debated.
METHODS
Population-based cohort study in the largest Health-Authority of Lazio region, Italy, on 946,156 residents aged 12+ (study period: 1 January 2021-10 January 2022). Vaccine effectiveness (VE) against any SARS-CoV-2 infection (symptomatic or asymptomatic) was estimated through multivariable negative-binomial models using unvaccinated person-time as a reference.
RESULTS
The primary vaccination cycle was completed by 81% of residents; of these, 45% received a booster dose. Vaccine coverages were lower for foreigners, and people living in deprived areas, families with children aged 0-11, and households size 1 or 6+. Overall, VE waned from 71% (95% Confidence Interval (CI) 70-73%) 1 month after the second dose to 43% (CI 41-45%) after 4 months and 24% (CI 21-27%) after 6 months, especially in the elderly aged 70+. We observed a prompt restore of VE 15-19 days after the booster dose (69%, CI 67-70%).
CONCLUSIONS
Our results support the recommendation of a booster dose 4 months after completion of the primary cycle, giving priority to elderly and fragile individuals. The lower vaccine coverage among social disadvantaged subgroups suggests the need of targeted communication and interventions.

Identifiants

pubmed: 35584901
doi: 10.1080/14760584.2022.2080057
doi:

Substances chimiques

COVID-19 Vaccines 0
Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1147-1157

Auteurs

Valeria Fano (V)

Department of Public Health, Local Health Authority Asl Roma 2, Rome, Italy.

Enzo Coviello (E)

Medical Doctor, Bari, Italy.

Dario Consonni (D)

Epidemiology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Alessandro Agresta (A)

Regional Service for Epidemiology, Surveillance and Control of Infectious Diseases, Lazio Region, Italy.

Nicola Orsini (N)

Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.

Alessia Crielesi (A)

Department of Public Health, Local Health Authority Asl Roma 2, Rome, Italy.

Antonio Salvatore Miglietta (AS)

Department of Public Health, Local Health Authority Asl Roma 2, Rome, Italy.

Caterina Pasqua (C)

Department of Public Health, Local Health Authority Asl Roma 2, Rome, Italy.

Francesco Vairo (F)

Regional Service for Epidemiology, Surveillance and Control of Infectious Diseases, Lazio Region, Italy.

Fabio Vivaldi (F)

Department of Public Health, Local Health Authority Asl Roma 2, Rome, Italy.

Giuseppe De Angelis (G)

Department of Public Health, Local Health Authority Asl Roma 2, Rome, Italy.

Giovanni Colaiocco (G)

Department of Public Health, Local Health Authority Asl Roma 2, Rome, Italy.

Massimo Fabiani (M)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH